NTRK gene fusion

Fusions involving NTRK1, NTRK2 or NTRK3 detected by sequencing, FISH or pan-TRK immunohistochemistry; used as a tissue-agnostic predictive marker for TRK inhibitors in solid tumors.

CI-BIO-00000023NTRK1 graph →NTRK2 graph →NTRK3 graph →NCIt C183255 Tumor-agnostic · 8 approval rows

Also calledNTRK fusion-positive · TRK fusion · ETV6-NTRK3 · NTRK1/2/3 fusion

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (8)

Entrectinib EU EMA · Jul 31, 2020 · drug + indication textRegulatory approved
Entrectinib US FDA · Oct 20, 2023 · drug + indication textRegulatory approved
Entrectinib US FDA · Aug 15, 2019 · drug + indication textRegulatory approved
Larotrectinib EU EMA · Sep 19, 2019 · drug + indication textRegulatory approved
Larotrectinib US FDA · Nov 26, 2018 · drug + indication textRegulatory approved
Larotrectinib US FDA · Nov 26, 2018 · drug + indication textRegulatory approved
Repotrectinib EU EMA · Jan 13, 2025 · drug + indication text

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Neoplasm	24	24	—	—	0 / 3 / 1 / 20 / 0
Infantile Fibrosarcoma	13	8	—	5	2 / 2 / 9 / 0 / 0
Solid Neoplasm	13	13	—

Derived

Drugs with predictive evidence (10)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
LarotrectinibSmall Molecule	55	48	7	A	48 / 14	Acute Myeloid Leukemia, Anaplastic Ependymoma, B Lymphoblastic Leukemia/Lymphoma, Breast Secretory Carcinoma +18
EntrectinibSmall Molecule	43	36	7	A	36 / 16	Acute Myeloid Leukemia, Anaplastic Astrocytoma, Brain Glioblastoma, Colorectal Adenocarcinoma +14
RepotrectinibSmall Molecule	4	4	—	C	7 / 0	Lung Non-Small Cell Carcinoma, Malignant Neoplasm
CrizotinibSmall Molecule	4	3	1	C	2 / 2	Infantile Fibrosarcoma, Lung Adenocarcinoma, Malignant Neoplasm
LestaurtinibSmall Molecule	2	2	—	D	2 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
ALK/TRK Inhibitor TSR-011	1	—	1	D	0 / 2	Malignant Neoplasm
EtoposideSmall Molecule	1	1	—	C	1 / 0	B Lymphoblastic Leukemia/Lymphoma
Larotrectinib Regimen	1	1	—	A	1 / 0	Solid Neoplasm
MethotrexateSmall Molecule	1	1	—	C	1 / 0	B Lymphoblastic Leukemia/Lymphoma
TRK Inhibitor	1	1	—	C	1 / 0	Spindle Cell Sarcoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (105)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–100 of 105 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK1 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10096 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10097 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10098 fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM), AFAP1-NTRK2 (2.7nM), ETV6-NTRK2 (4.5nM), ETV6-NT… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10099 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib in cell viability assays: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK1 Fusion8
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11354 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11349 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Repotrectinib	Malignant NeoplasmALIAS
NTRK1 Fusion + NTRK1 F589L3
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11355 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11351 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Repotrectinib	Malignant NeoplasmALIAS
NTRK1 Fusion + NTRK1 G595R3
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11356 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11350 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Repotrectinib	Malignant NeoplasmALIAS
NTRK1 Fusion + NTRK1 G667C2
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11357 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11359 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
NTRK1 Fusion + NTRK1 F589L + NTRK1 G595R2
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11358 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11353 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
NTRK3 Fusion + NTRK3 G623R1
ALK/TRK Inhibitor TSR-011 + Crizotinib + Entrectinib + LarotrectinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID10093 BaF3 cells were transduced with an ETV6-NTRK3 fusion construct with or without the additional NTRK3 G623R resistance mutation. These cells were then treated with common Trk inhibitors to measure the r… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK1 Fusion5
Larotrectinib	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID2953 Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. Th… (full text at CIViC) PMID 26603524 · 2016 · Open in CIViC	civic
〃	Sarcoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID6569 In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 pati… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
Entrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A
NTRK1 Fusion2
Larotrectinib	Malignant Thyroid Gland Neoplasm	Predictive	C	Supports Sensitivity Response	4	accepted	EID11748 A 4.3-year-old girl had I-131–refractory papillary thyroid carcinoma (PTC). There was lymph node involvement and lung metastases. She underwent thyroidectomy and neck dissection, and administration of… (full text at CIViC) PMID 34237031 · Lee et al., 2021 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9589 This Phase I study (NCT02122913) enrolled 70 heavily pretreated adult patients (median age 59.5 years) with various advanced solid tumors. Among them, one patient was identified with a TPR::NTRK1 fusi… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK3 Fusion2
Entrectinib	Melanoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID11857 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with melanoma … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	3	accepted	EID7496 In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatme… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 Fusion1
Larotrectinib	Melanoma	Predictive	E	Supports Sensitivity Response	2	accepted	EID6392 In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas… (full text at CIViC) PMID 29683819 · Lezcano et al., 2018 · Open in CIViC	civic
NTRK1 Fusion1
Larotrectinib	Melanoma	Predictive	E	Supports Sensitivity Response	2	accepted	EID6393 In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas… (full text at CIViC) PMID 29683819 · Lezcano et al., 2018 · Open in CIViC	civic
NTRK1 Fusion1
Larotrectinib	Melanoma	Predictive	E	Supports Sensitivity Response	2	accepted	EID6394 In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas… (full text at CIViC) PMID 29683819 · Lezcano et al., 2018 · Open in CIViC	civic
NTRK1 Fusion5
Entrectinib	Myofibroma	Predictive	C	Supports Sensitivity Response	1	accepted	EID11861 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
Larotrectinib	Sarcoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID6101 Four patients with infantile fibrosarcoma and soft tissue sarcoma and a TPM3::NTRK1 fusion were treated with larotrectinib. All four patients had a partial or complete response in the target lesion. T… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
Larotrectinib Regimen	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports
NTRK2 Fusion1
Larotrectinib	Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID6098 One Patient with soft tissue sarcoma and a STRN-NTRK2 fusion had a partial Response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, child… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
NTRK1 Fusion2
Larotrectinib	Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID6102 One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study an… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
〃	Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID7420 In a pediatric phase 1 trial (NCT02637687), a boy aged 15 months with soft tissue sarcoma of the right upper thigh harbored the PDE4DIP-NTRK1 fusion. After resection and the failure of initial chemoth… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic
NTRK3 Fusion2
Entrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID11125 Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective r… (full text at CIViC) PMID 31838007 · Doebele et al., 2020 · Open in CIViC	civic
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID6568 This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall re… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic
NTRK2 Fusion2
Entrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	1	accepted	EID11222 54 patients aged 18 or older with metastatic or locally advanced NTRK-fusion positive solid tumours (including ten tumour types and 19 unique histologies) were enrolled in one of three phase 1 or 2 tr… (full text at CIViC) PMID 31838007 · Doebele et al., 2020 · Open in CIViC	civic
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	2	accepted	EID10392 A pooled analysis of three phase 1/2 clinical trials investigating the efficacy and safety of larotrectinib in 159 NTRK fusion positive solid tumor patients (1 month - 84 years old) confirmed larotrec… (full text at CIViC) PMID 32105622 · Hong et al., 2020 · Open in CIViC	civic
NTRK1 Fusion + NTRK2 Fusion + NTRK3 FusionNTRK1 NTRK3 NTRK21
Entrectinib	Solid NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID12071 In the STARTRK-NG (NCT02650401) phase 1/2 trial, 43 pediatric and young adult patients (age <22 years) with recurrent or refractory solid tumors, including primary CNS tumors, were evaluated for respo… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
NTRK1 Amplification1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID10170 In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK3 Fusion1
Entrectinib	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID10635 Of 351 primary thyroid carcinoma patients assessed by targeted gene rearrangement next-generation assay, 11 cases (3.1%) had NTRK rearrangement. Only one case of EML4::NTRK3 fusion (e2,e13) with an in… (full text at CIViC) PMID 32457407 · Chu et al., 2020 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (146)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

emaRegulatory5 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Entrectinib	EU EMA	Tumor-agnosticLung Non-Small Cell Carcinoma	Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.conditional	approved	Jul 31, 2020	ema
Larotrectinib	EU EMA	Tumor-agnostic	Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.conditional	approved	Sep 19, 2019	ema
Repotrectinib

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (93)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 45 recruiting · 29 active phase 3 · 344 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 51–93 of 93 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07599007	Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion	not yet recruiting	—	10	Bristol-Myers SquibbINDUSTRY	1	May 20, 2026	clinicaltrials
NCT04380636	Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)	active not recruiting	Phase 3	870	Merck Sharp & Dohme LLCINDUSTRY	26	May 15, 2026	clinicaltrials
NCT06528691	Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors	recruiting	Phase 2	52	St. Jude Children's Research HospitalOTHER	4	May 13, 2026	clinicaltrials
NCT04898894	Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia	active not recruiting	Phase 1	37	St. Jude Children's Research HospitalOTHER	1	Apr 28, 2026	clinicaltrials
NCT05396859	Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	active not recruiting	Phase 1	13	OHSU Knight Cancer InstituteOTHER	1	Apr 27, 2026	clinicaltrials
NCT03164057	A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia	active not recruiting	Phase 2	206	St. Jude Children's Research HospitalOTHER	1	Apr 23, 2026	clinicaltrials
NCT06564324	A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients	recruiting	Phase 3	194	Nuvation Bio Inc.INDUSTRY	1	Apr 13, 2026	clinicaltrials
NCT03793478	Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood	active not recruiting	Phase 1 / Phase 2	65	Daiichi SankyoINDUSTRY	10	Apr 1, 2026	clinicaltrials
NCT05160922	Crizotinib Continuation Clinical Study	active not recruiting	Phase 4	27	PfizerINDUSTRY	5	Mar 30, 2026	clinicaltrials
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR)	recruiting	Phase 2	720	Canadian Cancer Trials GroupNETWORK	1	Mar 27, 2026	clinicaltrials
NCT04655404	A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion	recruiting	Early Phase 1	15	Nationwide Children's HospitalOTHER	5	Mar 18, 2026	clinicaltrials
NCT03970096	Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	recruiting	Phase 2	120	Fred Hutchinson Cancer CenterOTHER	1	Mar 12, 2026	clinicaltrials
NCT02574728	Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors(AflacST1502)	active not recruiting	Phase 2	46	Emory UniversityOTHER	1	Mar 2, 2026	clinicaltrials
NCT04469530	Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors(AflacST1903)	recruiting	Phase 2	55	Emory UniversityOTHER	1	Feb 27, 2026	clinicaltrials
NCT03121014	Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes	active not recruiting	Phase 2	38	University of Illinois at ChicagoOTHER	1	Jan 13, 2026	clinicaltrials
NCT05106296	Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer	recruiting	Phase 1	37	Theodore S. JohnsonOTHER	1	Jan 9, 2026	clinicaltrials
NCT04049669	Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG	active not recruiting	Phase 2	130	Theodore S. JohnsonOTHER	1	Jan 8, 2026	clinicaltrials
NCT02201992	Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)	active not recruiting	Phase 3	166	ECOG-ACRIN Cancer Research GroupNETWORK	3	Dec 19, 2025	clinicaltrials
NCT03834961	Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	active not recruiting	Phase 2	33	Children's Oncology GroupNETWORK	2	Dec 2, 2025	clinicaltrials
NCT03052608	A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC	active not recruiting	Phase 3	296	PfizerINDUSTRY	23	Nov 25, 2025	clinicaltrials
NCT05770544	DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Nov 24, 2025	clinicaltrials
NCT05783323	Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer	recruiting	Phase 2	13	Children's Hospital of PhiladelphiaOTHER	1	Nov 14, 2025	clinicaltrials
NCT06128070	Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	recruiting	Phase 2	40	City of Hope Medical CenterOTHER	1	Oct 31, 2025	clinicaltrials
NCT02605421	Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma	recruiting	Phase 2	12	Masonic Cancer Center, University of MinnesotaOTHER	1	Oct 21, 2025	clinicaltrials
NCT02767804	eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients	active not recruiting	Phase 3	290	Xcovery Holdings, Inc.INDUSTRY	20	Oct 14, 2025	clinicaltrials
NCT07199959	Study on the Mechanism of Acquired Resistance of Entrectinib	recruiting	—	38	Fudan UniversityOTHER	1	Sep 30, 2025	clinicaltrials
NCT04765098	Tamoxifen Versus Etoposide After First Recurrence in GBM Patients	recruiting	Phase 2	60	AHS Cancer Control AlbertaOTHER	1	Jun 26, 2025	clinicaltrials
NCT00470223	Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma(OS2006)	active not recruiting	Phase 3	318	UNICANCEROTHER	1	Jun 8, 2025	clinicaltrials
NCT06082635	TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)	active not recruiting	Phase 3	321	Shenzhen TargetRx Co., Ltd.INDUSTRY	1	May 18, 2025	clinicaltrials
NCT04314219	Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients(PTCy-PMAT)	recruiting	Phase 3	264	King Faisal Specialist Hospital & Research CenterOTHER	1	Mar 13, 2025	clinicaltrials
NCT03944772	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD)	active not recruiting	Phase 2	247	AstraZenecaINDUSTRY	9	Jan 30, 2025	clinicaltrials
NCT05476770	Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	recruiting	Phase 1	54	Therapeutic Advances in Childhood Leukemia ConsortiumOTHER	2	Dec 6, 2024	clinicaltrials
NCT06694129	Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC	not yet recruiting	—	40	National Cancer Center, ChinaOTHER	0	Nov 19, 2024	clinicaltrials
NCT05522582	Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors	active not recruiting	Phase 2	50	Yancheng First People's HospitalOTHER	1	Oct 26, 2024	clinicaltrials
NCT04322890	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU)	recruiting	Phase 2	6,000	Hunan Province Tumor HospitalOTHER	1	Oct 22, 2024	clinicaltrials
NCT05014464	ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma(ATPase)	recruiting	Phase 2	90	Hunan Province Tumor HospitalOTHER	1	Sep 20, 2024	clinicaltrials
NCT06221683	Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML(GMCAII)	recruiting	Phase 2	500	Children's Hospital of Soochow UniversityOTHER	1	Aug 22, 2024	clinicaltrials
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE)	recruiting	Phase 2	250	Helsinki University Central HospitalOTHER	1	Jul 15, 2024	clinicaltrials
NCT06254599	A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC	not yet recruiting	Phase 3	255	Shouyao Holdings (Beijing) Co. LTDOTHER	1	Feb 12, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT05725200	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT)	recruiting	Phase 2	40	Oslo University HospitalOTHER	1	Feb 21, 2023	clinicaltrials
NCT05303727	Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma	not yet recruiting	Phase 2	64	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Jul 1, 2022	clinicaltrials
NCT01704716	High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)	recruiting	Phase 3	3,300	St. Anna KinderkrebsforschungOTHER	20	Oct 23, 2020	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (8)

Associated cancers (32)

Drugs with predictive evidence (10)

Predictive evidence items (105)

Approvals mentioning the linked drugs (146)

Active trials (93)

Linked publications (77)